Intelligent Insulin Management System

A next-generation insulin management system leveraging AI, machine learning, and genomics to provide personalized, real-time, and predictive glycemic management for patients with diabetes.

The original patent for insulin management addressed the need for efficient insulin dosing, but it relied on manual calculations and limited data inputs. The new inventive concept tackles the limitations of the original patent by incorporating advanced technologies to provide more accurate, personalized, and proactive insulin management.

The Intelligent Insulin Management System consists of a neural network trained on a large dataset of patient glucose levels and insulin dosing regimens. This network predicts optimal insulin dosing regimens for individual patients based on real-time glucose level data, medical history, and genomic profiles. The system also includes a wearable device for continuous glucose monitoring and insulin dosing, a cloud-based platform for collaborative glycemic management, and a machine learning model for predictive glycemic management. These components work in tandem to provide healthcare professionals with a comprehensive tool for managing patient glycemic levels.

The new inventive concept introduces the use of neural networks, genomics, and machine learning algorithms to insulin management, enabling personalized and predictive glycemic management. This represents a significant departure from the original patent, which relied on manual calculations and limited data inputs.

Alternative embodiments of the Intelligent Insulin Management System could include the use of different machine learning algorithms, integration with electronic health records, or the development of a mobile application for patient self-management. Variations could also include the use of different sensors or wearable devices for glucose monitoring.

The Intelligent Insulin Management System has significant commercial potential in the diabetes management market, which is projected to reach $12.6 billion by 2025. The system could be marketed to healthcare providers, pharmaceutical companies, and medical device manufacturers, offering a competitive advantage in terms of personalized and proactive glycemic management.